GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » Earnings Power Value (EPV)

Ekso Bionics Holdings (Ekso Bionics Holdings) Earnings Power Value (EPV) : $-7.32 (As of Mar24)


View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings Earnings Power Value (EPV)?

As of Mar24, Ekso Bionics Holdings's earnings power value is $-7.32. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Ekso Bionics Holdings Earnings Power Value (EPV) Historical Data

The historical data trend for Ekso Bionics Holdings's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ekso Bionics Holdings Earnings Power Value (EPV) Chart

Ekso Bionics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.71 -30.68 -13.15 -10.51 -9.03

Ekso Bionics Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.08 -9.77 -9.34 -9.03 -7.32

Competitive Comparison of Ekso Bionics Holdings's Earnings Power Value (EPV)

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ekso Bionics Holdings's Earnings Power Value (EPV) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's Earnings Power Value (EPV) falls into.



Ekso Bionics Holdings Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Ekso Bionics Holdings's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 13.08
DDA 1.02
Operating Margin % -122.03
SGA * 25% 4.43
Tax Rate % 0.00
Maintenance Capex 0.12
Cash and Cash Equivalents 8.80
Short-Term Debt 1.62
Long-Term Debt 5.22
Shares Outstanding (Diluted) 17.42

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -122.03%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $13.08 Mil, Average Operating Margin = -122.03%, Average Adjusted SGA = 4.43,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 13.08 * -122.03% +4.43 = $-11.52871062 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 0.00%, and "Normalized" EBIT = $-11.52871062 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -11.52871062 * ( 1 - 0.00% ) = $-11.52871062 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 1.02 * 0.5 * 0.00% = $0 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -11.52871062 + 0 = $-11.52871062 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Ekso Bionics Holdings's Average Maintenance CAPEX = $0.12 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Ekso Bionics Holdings's current cash and cash equivalent = $8.80 Mil.
Ekso Bionics Holdings's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 5.22 + 1.62 = $6.842 Mil.
Ekso Bionics Holdings's current Shares Outstanding (Diluted Average) = 17.42 Mil.

Ekso Bionics Holdings's Earnings Power Value (EPV) for Mar24 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -11.52871062 - 0.12)/ 9%+8.80-6.842 )/17.42
=-7.32

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -7.3174762041449-1.10 )/-7.3174762041449
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Ekso Bionics Holdings  (NAS:EKSO) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Ekso Bionics Holdings Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Traded in Other Exchanges
Address
101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.
Executives
Jerome Wong officer: Interim CFO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis officer: President & COO C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman director
Jason C Jones officer: VP of Product Development EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna director 140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw officer: See Remarks 1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen director C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd 10 percent owner ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach director, officer: Chief Executive Officer 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck director 10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini officer: VP of Sales, Americas C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc 10 percent owner C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022